Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
Not Confirmed
Not Confirmed
09-11 April, 2025
Not Confirmed
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Not Confirmed
Not Confirmed
01-03 April, 2025
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
09-11 April, 2025
Industry Trade Show
Not Confirmed
01-03 April, 2025
Peptide-Based Therapeu...Peptide-Based Therapeutics Summit
Industry Trade Show
Not Confirmed
01-03 April, 2025
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/our-unmatched-efficiency-and-track-record-of-faster-dmf-filings-give-our-customers-a-critical-competitive-advantage
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/molecular-glue-degraders-lilly-abbvie-sign-billion-dollar-deals-bms-leads-with-three-late-stage-drugs
15 Nov 2023
// Nick Paul Taylor FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/jazz-locks-arms-gsk-spinout-autifony-putting-771m-form-neuroscience-discovery-pact
13 Jun 2023
// BUSINESSWIRE
Details:
The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Lead Product(s): Undisclosed
Therapeutic Area: Neurology Brand Name: Undisclosed
Study Phase: DiscoveryProduct Type: Undisclosed
Sponsor: Jazz Pharmaceuticals
Deal Size: $770.0 million Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 14, 2023
Details : The agreement aims to discover and develop drug candidates targeting two different ion channel targets associated with neurological disorders. Autifony will lead drug discovery and preclinical development activities on the two targets.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
November 14, 2023
Details:
Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Lead Product(s): AUT00206
Therapeutic Area: Otolaryngology (Ear, Nose, Throat) Brand Name: AUT00206
Study Phase: Phase IProduct Type: Other Small Molecule
Sponsor: Boehringer Ingelheim GmbH
Deal Size: $50.1 million Upfront Cash: $29.5 million
Deal Type: Termination August 26, 2020
Lead Product(s) : AUT00206
Therapeutic Area : Otolaryngology (Ear, Nose, Throat)
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Boehringer Ingelheim GmbH
Deal Size : $50.1 million
Deal Type : Termination
Autifony Therapeutics Regains Rights to Clinical Stage Kv3 Programme
Details : Boehringer Ingelheim will not be exercising its Option under the Option for Asset Purchase Agreement which was signed by the two companies in December 2017. Autifony has regained full rights to its Kv3 programme.
Product Name : AUT00206
Product Type : Other Small Molecule
Upfront Cash : $29.5 million
August 26, 2020
ABOUT THIS PAGE